Meeting
2022 ASCO Genitourinary Cancers Symposium
Diagnosis codes overestimate the burden of prostate cancer cases.
Authors
Tori Anglin-Foote
VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT
Tori Anglin-Foote , Kyung Min Lee , Brian Robison , Patrick Alba , Scott L. DuVall , Julie Ann Lynch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 72)
DOI
10.1200/JCO.2022.40.6_suppl.072
Abstract #
72
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Methylated DNA markers in urine aid in the selective identification of patients with prostate cancer as well as clinically significant pathology.
First Author: Paras Shah
Poster
2020 Genitourinary Cancers Symposium
Pathologic outcomes of MRI invisible tumors in prostate cancer.
First Author: Sandeep Gurram
Poster
2019 ASCO Quality Care Symposium
An NLP tool to identify molecular diagnostic testing in veterans with stage IV NSCLC.
First Author: Julie Ann Lynch
Poster
2019 Genitourinary Cancers Symposium
MRI-TRUS fusion-guided biopsy in obese patients: Does it reduce risk of prostate cancer upgrade on final pathology compared to systematic 12-core biopsy?
First Author: Samuel A Gold